NancyMaureenHardyMDFACP

Oncology • Baltimore, MD

Associate Professor, Medicine, Greenebaum Cancer Center

Join to view full profile

Dr. Hardy is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hardy's full profile

Already have an account?

Office
22 S Greene St
Baltimore, MD 21201
Phone+1 410-328-6841

Fax+1 410-328-6841

Education & Training

National Cancer InstituteFellowship, Stem Cell Transplantation and Immunotherapy, 2003 - 2006
National Institutes of Health Clinical CenterFellowship, Infectious Disease, 1999 - 2003
Duke University HospitalFellowship, Hematology and Medical Oncology, 1998 - 2001
Duke University HospitalFellowship, Hematology and Medical Oncology, 1998 - 1999
Duke University HospitalResidency, Internal Medicine, 1995 - 1998
University of Washington School of MedicineClass of 1995

Certifications & Licensure

MD State Medical License 2004 - 2026
WA State Medical License 2010 - 2024
NC State Medical License 1998 - 2022
DC State Medical License 2013 - 2014

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014

Clinical Trials

Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells Start of enrollment: 2010 Dec 10
Recruiting
Phase 2
Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation Start of enrollment: 2011 Mar 30
Terminated
MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC Start of enrollment: 2015 Nov 01
Completed
Phase 1
Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination Start of enrollment: 2015 Dec 01
Recruiting
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Start of enrollment: 2016 Dec 01
Completed
Phase 2
Safety Evaluation of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation Start of enrollment: 2017 Feb 08
Completed
Phase 1
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease Start of enrollment: 2017 Jul 19
Completed
Phase 3
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous TransplantatIon in Subjects With MM Start of enrollment: 2018 Mar 23
Active, not recruiting
Phase 3
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease Start of enrollment: 2018 Feb 27
Terminated
Phase 1
DALY II USA/ MB-CART2019.1 for DLBCL Start of enrollment: 2021 May 25
Recruiting
Phase 2
Roles: Contact
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU Start of enrollment: 2024 May 15
Not yet recruiting
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

114 citations
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Trans...
Marcos de Lima, David L. Porter, Minoo Battiwalla, Michael R. Bishop, Sergio Giralt
Biology of Blood and Marrow Transplantation. 2014-01-01
627 citations
NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
Aaron P. Rapoport, Edward A. Stadtmauer, Gwendolyn Binder-Scholl, Olga Goloubeva, Dan T. Vogl
Nature Medicine. 2015-07-20
454 citations
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
James N. Kochenderfer, Mark E. Dudley, Robert O. Carpenter, Sadik H. Kassim, Jeremy J. Rose
Blood. 2013-12-12

Abstracts/Posters

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predicti...
Nancy M. Hardy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain Barrier
Nancy M. Hardy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019